ALXN News Alert Alexion Pharmaceuticals (ALXN) 181.96 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexion Pharmaceuticals (ALXN) 181.96 $ALXN

All-Time Highs For Dow, S&P 500; Nasdaq Lags
at Investor's Business Daily - Tue Dec 23, 4:02PM CST
The Dow Jones industrial average and the S&P 500 hit new all-time highs Tuesday, but the Nasdaq finished lower. Volume was lower on both exchanges, according to preliminary data. Department stores were the best-performing industry group, up nearly...
DDS: 122.53 (+0.53), ALXN: 181.96 (+3.09), XOM: 93.78 (-0.81), M: 64.26 (+0.22), CVX: 113.47 (-0.48)

SmarTrend Watching for Potential Rebound in Shares of Alexion Pharmaceuticals After 4.93% Loss
Comtex SmarTrend(R) - Tue Dec 23, 3:57PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $176.61 to a high of $189.89. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $184.00 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 181.96 (+3.09)

Toys, Department Stores Rock, But Biotechs Tumble
at Investor's Business Daily - Tue Dec 23, 11:06AM CST
The euphoria over third-quarter GDP growth of 5% evaporated Tuesday morning, leaving stocks trading mixed at midday, with the Nasdaq leading other indexes off their best levels. The Nasdaq was off 0.1% ,the S&P 500 rose 0.3% and the Dow Jones...
HAS: 55.25 (+0.03), BIIB: 340.89 (+5.13), PCYC: 121.84 (+1.15), M: 64.26 (+0.22), CELG: 109.60 (+3.48), DDS: 122.53 (+0.53), ESRX: 85.48 (-0.40), MAT: 30.22 (-0.16), GILD: 91.29 (+1.84), JCP: 6.50 (-0.24), ALXN: 181.96 (+3.09), ABBV: 66.21 (+1.86)

Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid
PR Newswire - Tue Dec 23, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alkermes PLC (NASDAQ: ALKS), and Cepheid (NASDAQ: CPHD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 22, 2014, the NASDAQ Composite ended at 4,781.42, up 0.34%, the Dow Jones Industrial Average advanced 0.87%, to finish the day at 17,959.44, and the S&P 500 closed at 2,078.54, up 0.38%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 807.53, down 1.15%, while the index has advanced 8.06% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 99.23 (+1.23), SRPT: 13.88 (+0.47), CPHD: 53.39 (+0.51), ALXN: 181.96 (+3.09), ALKS: 56.16 (+1.02)

Insider Trading Alert - SMRT, FII And ALXN Traded By Insiders
at The Street - Mon Dec 22, 12:50PM CST
Stocks with insider trader activity include SMRT, FII and ALXN
FII: 33.86 (+0.26), ALXN: 181.96 (+3.09), SMRT: 14.67 (-0.04)

Alnylam Pharmaceuticals Continues To Post Encouraging Results
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 11:15AM CST

ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), ALXN: 181.96 (+3.09), SNY: 46.35 (+0.50)

J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
at The Street - Mon Dec 22, 7:23AM CST
Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.
VRX: 140.33 (-0.22), BMRN: 88.18 (+0.89), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), BMY: 59.15 (-0.01)

The Market's 10 Best Stocks
Dan Caplinger, The Motley Fool - Motley Fool - Sun Dec 21, 7:02AM CST
Source: Wikimedia Commons. Investors are always searching for the best possible stocks. That's because if you can identify a winning stock before it takes off, it can have a life-changing impact on your finances. In order to find those stocks,...
NFLX: 342.10 (+5.67), NEU: 405.00 (+5.94), MNST: 112.56 (+0.52), OPK: 9.63 (+0.21), GMCR: 137.65 (+1.10), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), AAPL: 112.01 (-0.53), REGN: 400.12 (+6.07), PCLN: 1,149.78 (+2.17)

Alexion's Rare Disease Model Analyzed
William Meyers - at Seeking Alpha - Thu Dec 18, 2:23PM CST

GILD: 91.29 (+1.84), ALXN: 181.96 (+3.09)

Insider Trading Alert - DXCM, ALXN And FRGI Traded By Insiders
at The Street - Wed Dec 17, 12:45PM CST
Stocks with insider trader activity include DXCM, ALXN and FRGI
DXCM: 54.94 (+0.99), ALXN: 181.96 (+3.09), FRGI: 56.97 (+0.47)

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.69 (+0.01), CBST: 100.29 (-0.09), SPHS: 0.46 (+0.02), CCXI: 6.64 (-0.04), ALXN: 181.96 (+3.09), EXEL: 1.29 (-0.01)

3 Companies Growing Faster Than MannKind Corporation
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 6:03AM CST
Source: MannKind. MannKind shareholders have had quite the year. After more than doubling in the first half of the year, shares have since given back all of their gains and sit essentially unchanged. Despite the stalemate, MannKind could be on...
AKRX: 36.47 (+0.43), ALXN: 181.96 (+3.09), ACOR: 39.14 (+0.74), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)

Alexion Announces New Share Repurchase Program of $500M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:55PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized by its board of directors.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), ALXN: 181.96 (+3.09)

Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:15PM CST
Alexion (ALXN) announced that Soliris has received orphan drug designation in Japan for the treatment of myasthenia gravis.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), ALXN: 181.96 (+3.09), AMGN: 160.67 (+3.15)

Alexion to buy back shares
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:01AM CST

ALXN: 181.96 (+3.09)

Alexion Announces $500 Million Share Repurchase Program
Business Wire - Mon Dec 15, 5:30AM CST
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company's Board of Directors has authorized a new share repurchase program of up to $500 million. The new share repurchase program will take effect upon completion of the Company's current program, which has approximately $22 million remaining of its previously authorized $400 million.
ALXN: 181.96 (+3.09)

Meet 5 Top Biotech Stocks Holding Up In Shaky Market
at Investor's Business Daily - Sat Dec 13, 7:02AM CST
Everyone gets sick, and drastic health problems call for more drastic treatment. That's partly why several top-rated biotech stocks in today's IBD 50 list have held up well despite recent market pressue. Alexion Pharmaceuticals (ALXN), the fourth...
BIIB: 340.89 (+5.13), GILD: 91.29 (+1.84), ALXN: 181.96 (+3.09), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), CELG: 109.60 (+3.48)

United Therapeutics: Will It Pass Peers In 2015?
at Investor's Business Daily - Fri Dec 12, 5:11PM CST
Biomed company United Therapeutics is in a strong industry group, and that's a problem. United Therapeutics' (UTHR) three-year earnings growth rate is 26%, good enough for an EPS Rating of 89. However, in a leading group, "good enough" isn't good...
BIIB: 340.89 (+5.13), UTHR: 130.22 (+2.40), ALXN: 181.96 (+3.09), TEVA: 57.09 (+0.33), CELG: 109.60 (+3.48)

IBD 50: Growth Stocks Fight The Fight In Weak Tape
at Investor's Business Daily - Fri Dec 12, 5:11PM CST
The IBD 50's four-week winning streak came to an end Friday as the index of leading growth stocks lost 3% for the week. It was a tough week for the broad market, too, as the S&P 500 lost 3.5%. The IBD 50 generally has had a hard time keeping up with...
MNST: 112.56 (+0.52), SWKS: 74.32 (+0.92), FB: 80.77 (+0.16), AFSI: 54.21 (-0.05), BITA: 72.57 (+0.36), CDW: 35.75 (+0.14), CELG: 109.60 (+3.48), BIDU: 230.98 (-2.18), ALXN: 181.96 (+3.09), FFIV: 135.11 (+1.17), AAPL: 112.01 (-0.53), ROST: 92.72 (-0.60), AVGO: 100.72 (-0.06)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 65

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 86

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 133

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 121

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 87

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading

Top 5 Most Recently Viewed Articles

American Teachers Alliance Initiates Empowering Programs for Students

Updated Category News Views 143

Empowering Future Educators with College Chapters In a progressive move to inspire and support the upcoming generation of teachers, the American Teachers Alliance (ATA) has launched a significant initiative aimed at engaging college students across universities. This initiative introduces college student chapters, fostering a community where aspiring educators can enhance...

Continue Reading
Enhancing Enterprise Collaboration: Progress ShareFile and Microsoft 365

Updated Category News Views 190

Introduction to Progress ShareFile's New Features Progress, a leading provider of AI-driven digital experience and infrastructure software, is excited to announce significant advancements to its ShareFile platform. The recent updates mark a transformative leap in how enterprises collaborate using Microsoft 365, empowering teams to work more securely and efficiently. Deep...

Continue Reading
Shareholder Alert: Investigations on Major Mergers for 2025

Updated Category News Views 314

Investigating Significant Mergers in 2025 In the financial landscape, the merging of companies can significantly impact shareholders. Recognizing the importance of every shareholder's voice, we delve into several notable mergers that are under scrutiny as we approach votes critical to shareholders. As many companies opt for merger routes, understanding the implications of...

Continue Reading
Explore the Vibrant Daylight Shows Series in NYC's Hotspots

Updated Category News Views 181

Unveiling the Daylight Shows at Daylight Studio Experience the vibrant world of creativity at Daylight Studio, a prominent event venue nestled in two of New York City's most dynamic areas, Hudson Yards and Flatiron. With years of experience in supporting film, fashion, and artistic endeavors, Daylight Studio has secured its place as a go-to location for creatives and...

Continue Reading
Ventyx Biosciences Begins Phase 2a Trial for Parkinson’s Treatment

Updated Category News Views 138

Ventyx Biosciences Begins Phase 2a Trial for VTX3232 Ventyx Biosciences, Inc. (Nasdaq: VTYX), a company focused on creating innovative oral treatments for various inflammatory diseases, has announced the start of dosing for its Phase 2a clinical trial of VTX3232. This important trial is centered on individuals who have been diagnosed with the early stages of Parkinson’s...

Continue Reading